
Axsome Therapeutics (AXSM) Stock Forecast & Price Target
Axsome Therapeutics (AXSM) Analyst Ratings
Bulls say
Axsome Therapeutics Inc. reported third-quarter revenues of $136.1 million, significantly exceeding consensus estimates and demonstrating a robust year-over-year growth of 69% and a quarter-over-quarter increase of 14%. The company has improved payer coverage to 85%, which enhances the commercial potential of its therapies, particularly with the positive outcomes from ongoing Phase III studies, including the FOCUS study for adult ADHD. Furthermore, projections indicate that revenue will outpace operating costs, potentially leading to improved operating margins and a forecasted cash flow positivity by 2026.
Bears say
Axsome Therapeutics Inc. faces a negative outlook primarily due to a revised revenue forecast for 2025, reflecting a modest decline from previous estimates, indicating potential market challenges. Several significant risks threaten the company's performance, including lower-than-expected market access for its lead product AUVELITY, setbacks in key clinical trials, and challenges in securing timely approvals for pipeline candidates such as AXS-12 and AXS-14. Additionally, the company may encounter long-term dilution risks and competitive pressures that could hinder its commercial success within the CNS disorder treatment landscape.
This aggregate rating is based on analysts' research of Axsome Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Axsome Therapeutics (AXSM) Analyst Forecast & Price Prediction
Start investing in Axsome Therapeutics (AXSM)
Order type
Buy in
Order amount
Est. shares
0 shares